Bayer Seals $66 Billion Deal for Monsanto

The transcript discusses the Bayer-Monsanto deal, highlighting regulatory challenges and market reactions. It covers the potential for the deal to be blocked by regulators in the US and EU, despite divestitures. The pricing of the deal is analyzed, noting a significant premium and market expectations. The transcript also addresses the impact of asset sales and the importance of a $2 billion breakup fee, with other companies preparing to purchase divested assets.

What was the price range analysts expected for Monsanto's deal, and how did it compare to the actual price?

What implications does the potential blocking of the deal have for Monsanto and the market?